Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) COGS-to-Revenue : 0.18 (As of Nov. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings COGS-to-Revenue?

Cannabis Bioscience International Holdings's Cost of Goods Sold for the six months ended in Nov. 2023 was $0.02 Mil. Its Revenue for the six months ended in Nov. 2023 was $0.14 Mil.

Cannabis Bioscience International Holdings's COGS to Revenue for the six months ended in Nov. 2023 was 0.18.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cannabis Bioscience International Holdings's Gross Margin % for the six months ended in Nov. 2023 was 82.48%.

Cannabis Bioscience International Holdings COGS-to-Revenue Historical Data

The historical data trend for Cannabis Bioscience International Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings COGS-to-Revenue Chart

Cannabis Bioscience International Holdings Annual Data

Trend

Dec06

Dec07

May09

May10

May11

COGS-to-Revenue

0.50

0.81

0.76

0.68

Cannabis Bioscience International Holdings Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	May09	Nov09	May10	Nov10	May11	Nov11	Nov22	Nov23
COGS-to-Revenue	Get a 7-Day Free Trial							0.72	0.62	0.66	0.24	0.18

Cannabis Bioscience International Holdings COGS-to-Revenue Calculation

Cannabis Bioscience International Holdings's COGS to Revenue for the fiscal year that ended in May. 2011 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	56.383	/	83.461
	=	0.68

Cannabis Bioscience International Holdings's COGS to Revenue for the quarter that ended in Nov. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.024	/	0.137
	=	0.18

Cannabis Bioscience International Holdings (OTCPK:CBIH) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cannabis Bioscience International Holdings's Gross Margin % for the six months ended in Nov. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.024 / 0.137
	=	82.48 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cannabis Bioscience International Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036

Website

https://www.cbih.net

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.